PET/MR of pediatric bone tumors: what the radiologist needs to know

Skeletal Radiol. 2023 Mar;52(3):315-328. doi: 10.1007/s00256-022-04113-6. Epub 2022 Jul 9.

Abstract

Integrated 2-deoxy-2-[fluorine-18]fluoro-D-glucose (18F-FDG) positron emission tomography (PET)/magnetic resonance (MR) imaging can provide "one stop" local tumor and whole-body staging in one session, thereby streamlining imaging evaluations and avoiding duplicate anesthesia in young children. 18F-FDG PET/MR scans have the benefit of lower radiation, superior soft tissue contrast, and increased patient convenience compared to 18F-FDG PET/computerized tomography scans. This article reviews the 18F-FDG PET/MR imaging technique, reporting requirements, and imaging characteristics of the most common pediatric bone tumors, including osteosarcoma, Ewing sarcoma, primary bone lymphoma, bone and bone marrow metastases, and Langerhans cell histiocytosis.

Keywords: Bone sarcoma; Magnetic resonance; PET/MR; Pediatric cancer; Positron emission tomography.

Publication types

  • Review

MeSH terms

  • Bone Neoplasms* / pathology
  • Child
  • Child, Preschool
  • Fluorodeoxyglucose F18*
  • Humans
  • Magnetic Resonance Imaging / methods
  • Magnetic Resonance Spectroscopy
  • Neoplasm Staging
  • Positron-Emission Tomography / methods
  • Radiologists
  • Radiopharmaceuticals

Substances

  • Fluorodeoxyglucose F18
  • Radiopharmaceuticals
  • Fluorine-18